- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01023815
Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids. (EVIDENCE)
Once-a-day Regimen or Steroid Withdrawal in de Novo Kidney Transplant Recipients Treated With Everolimus, Cyclosporine and Steroids: a 12-month, Prospective, Randomized, Multicenter, Open-label Study. The EVIDENCE Study (EVerolImus Once-a-Day rEgimen With Neoral Versus Corticosteroid Elimination).
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Ancona, Italië, 60100
- Novartis Investigative Site
-
Bologna, Italië
- Novartis Investigative Site
-
Brescia, Italië
- Novartis Investigative Site
-
Cagliari, Italië
- Novartis Investigative Site
-
Catania, Italië
- Novartis Investigative Site
-
Coppito, Italië
- Novartis Investigative Site
-
Firenze, Italië
- Novartis Investigative Site
-
Genova, Italië, 16132
- Novartis Investigative Site
-
Milano, Italië, 20122
- Novartis Investigative Site
-
Modena, Italië, 41100
- Novartis Investigative Site
-
Napoli, Italië
- Novartis Investigative Site
-
Novara, Italië, 28100
- Novartis Investigative Site
-
Padova, Italië
- Novartis Investigative Site
-
Palermo, Italië
- Novartis Investigative Site
-
Parma, Italië
- Novartis Investigative Site
-
Perugia, Italië, 06070
- Novartis Investigative Site
-
Pisa, Italië
- Novarits Investigative Site
-
Roma, Italië
- Novartis Investigative Site
-
Rome, Italië
- Novartis Investigative Site
-
Salerno, Italië
- Novartis Investigative Site
-
Sassari, Italië, 07100
- Novartis Investigative Site
-
Siena, Italië, 53100
- Novartis Investigative Site
-
Torino, Italië, 10126
- Novartis Investigative Site
-
Treviso, Italië
- Novartis Investigative Site
-
Udine, Italië
- Novartis InvestigativeSite
-
Varese, Italië
- Novartis Investigative Site
-
Verona, Italië
- Novartis Investigative Site
-
Vicenza, Italië
- Novartis Investigative Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion criteria:
- recipients of 1st or 2nd single kidney transplant
- donor age >14 years
- females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at Baseline (Visit 2), and are required to practice an approved method of birth control for the duration of the study and for a period of 2 months following discontinuation of study medication
- patientswho are willing and able to participate in the study and from whom written informed consent has been obtained
Exclusion criteria:
Exclusion criteria at screening (pre-transplantation, Visit 1):
- recipients of kidney-pancreas transplant, double kidney or any other transplant
- recipients of a 2nd kidney transplant who lost the 1st for immunological reasons
- focal segmental glomerulosclerosis (FSGS), primary oxaluria or other diseases (as cause of end stage renal failure - ESRF) at high risk of rapid recurrence or requiring continuous corticosteroid treatment
- recipients of A-B-O incompatible transplants
- historical or current peak PRA of >25% (current = 3 months)
- patients with already existing antibodies against the donor
- thrombocytopenia (platelets <75,000/mm³), absolute neutrophil count of <1,500/mm³, leucopenia (leucocytes <2,500/mm³), or hemoglobin <6 g/dL
- symptoms of significant somatic or mental illness. Inability to cooperate or communicate with the investigator, or to comply with the study requirements, or to give informed consent
- history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases
- patients who are HIV positive or Hepatitis B surface antigen positive (HbsAg); HCV positive patients receiving interferon and/or ribavirin
- evidence of severe liver disease (incl. abnormal liver enzyme profile, i.e. AST, ALT or total bilirubin >3 times UNL)
- evidence of drug or alcohol abuse
- body mass index (BMI) >35
- patients who need to be treated with drugs known to strongly interact with CsA and/or everolimus (as detailed in Appendix 2 of the protocol) should be excluded, if according the investigator this interferes with the objectives of the study
- women of child-bearing potential, UNLESS they are using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method
- pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>5 mIU/mL)
- use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
- history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
- patients with severe active infections or any other medical condition(s) that in the view of the investigator prohibits participation in the study (specify as required)
Additional exclusion criteria post-transplantation (Visit 2):
• graft not perfused or with thrombosis of the main vessels, according to angioscintigraphy or echocolordoppler within 48 hours after the end of surgical procedure
To avoid any possible influence of the confounding factors on the results of this study additional exclusion criteria at randomization were (Visit 5, Month 3):
- unsatisfactory renal function (CrCl according Cockcroft and Gault<40 mL/min)
- proteinuria ≥0.8 g/24 hrs
- steroid-resistant, humoral, moderate/severe (BANFF grade ≥II) biopsy proven acute rejections
- multiple (2 or more) biopsy proven or treated acute rejections or acute rejections leading to relevant loss of renal function
- acute rejection or impairment of renal function (increase of serum creatinine>30%) in the month preceding randomization
- severe/uncontrollable adverse events with suspected relationship to everolimus (e.g. anemia, oral aphtosis, arthralgia) for the control of which the investigator has planned the withdrawal of everolimus
- severe infections requiring hospitalization in the two weeks preceding randomization
poor compliance to prescribed treatments
- Other protocol-defined inclusion/exclusion criteria may apply
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Group A -Once-a-day regimen
Everolimus: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole daily dose of everolimus was taken in the morning, at the same time of the CsA and steroid dosing. At the Rand+1W visit, the everolimus dose was adjusted to reach and maintain everolimus blood levels between 5 and 8 ng/mL until end of Month 12. Cyclosporine: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole cyclosporine daily dose was taken in the morning. The dose was then adjusted to maintain C2 levels between 350 and 700 ng/mL. Prednisone: In patients randomized to Group A before Amendment 1 approval, the dose of prednisone was kept stable at 5 mg/day in the morning. |
Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg.
Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
Andere namen:
Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day.
CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg.
Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
Andere namen:
continuous steroids
|
Experimenteel: Group B - Steroid Withdrawal group
Everolimus: after randomization the everolimus dose was adjusted, if necessary, to maintain a C0 within 6-10 ng/mL until M12. Cyclosporine:after randomization the cyclosporine dose was adjusted to maintain CsA C2 levels within 300-500 ng/mL until M12. Prednisone: starting from Visit 5 (day 90 ± 28 days), oral prednisone was tapered until complete stop. It was recommended to taper prednisone by 1 mg/week until complete stop in 5 to 6 weeks. |
Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg.
Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
Andere namen:
Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day.
CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg.
Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
Andere namen:
continuous steroids
|
Actieve vergelijker: Group C - Standard twice-a-day group
Everolimus: after randomization the everolimus dose was adjusted, if necessary, in order to maintain a C0 within 6-10 ng/mL until M12. Cyclosporine: after randomization the cyclosporine dose was gradually adjusted to reach and maintain C2 blood levels of 200-450 ng/mL between Month 6 and Month 12. Prednisone: the dose of prednisone was kept stable at 5 mg/day in the morning. |
Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg.
Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
Andere namen:
Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day.
CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg.
Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
Andere namen:
continuous steroids
|
Experimenteel: Not Randomized Population (NRP)
NRP defined in whom a renal transplantation was performed, received at least one dose of study drug (everolimus) but who did not qualify for randomization at Visit 5, Day 90.
This group was addressed as "not randomized patients" (NRP) and described with respect to baseline characteristics, treatment and outcome variables.
|
Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg.
Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Treatment Failure Rate
Tijdsspanne: Between randomization (Month 3) and Month 12
|
Occurrence or not of treatment failure in each patient.
Treatment failure was defined as a composite endpoint of biopsy-proven acute rejection (a biopsy graded IA, IB, IIA, IIB or III according to Banff '97 grading with 2007 update), graft loss, death or lost to follow-up occurring after randomization (V5) and within M12 (V9).
|
Between randomization (Month 3) and Month 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Changes in the Estimated Glomerular Filtration Rate (eGFR) Between Randomization (Month 3) and Month 12
Tijdsspanne: Month 3 to Month 12
|
eGFR by Nankivell, in terms of descriptive statistics and change vs randomization visit - to compare the changes in the estimated GFR (Nankivell) between randomization and Month 12 in the steroid withdrawal group (Group B) to the change observed in the standard twice-a-day group (Group C), for non-inferiority
|
Month 3 to Month 12
|
Biopsy Proven Acute Rejection (BPAR) Rate Between Randomization and Month 12
Tijdsspanne: Month 3 to Month 12
|
Occurrence of BPAR (after randomization) between arm B (steroid withdrawal group) and arm c (standard twice-a-day group). BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III according to Banff 1997 grading with 2007 update. |
Month 3 to Month 12
|
Number of Participants With Graft and Patient Survival After Randomization
Tijdsspanne: Month 3 to Month 12
|
Graft Survival, calculated from the date of transplantation to the date of irreversible graft failure signified by return to long-term retransplantation or the date of the last follow-up during the period when the transplant was still functioning or to the date of death. Patient survival, calculated from the date of transplantation to the date of death or the date of the last follow-up. |
Month 3 to Month 12
|
Change in Estimated Creatine Clearance
Tijdsspanne: M3, M12
|
At each visit, estimated creatinine clearance was measured in the local laboratory to analyze the evolution of the renal function.
The following indirect measures of renal function were computed: estimated creatinine clearance according to Cockcroft and Gault formula and MDRD formula.
|
M3, M12
|
Change in Serum Creatinine
Tijdsspanne: M3, M12
|
Serum creatinine (a blood measurement) is an important indicator of renal health because it is an easily-measured by-product of muscle metabolism.
Measuring serum creatinine is a simple test and it is the most commonly used indicator of renal function.
|
M3, M12
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Anti-infectieuze middelen
- Enzymremmers
- Antireumatische middelen
- Antineoplastische middelen
- Immunosuppressieve middelen
- Immunologische factoren
- Dermatologische middelen
- Antischimmelmiddelen
- Calcineurineremmers
- Everolimus
- Cyclosporine
- Cyclosporines
Andere studie-ID-nummers
- CRAD001AIT12
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Niertransplantatie
-
Postgraduate Institute of Medical Education and...VoltooidType 1 HEPATO RENAL SYNDROOM (HRS)Indië
-
Bristol-Myers SquibbVoltooidTrombose | Nierfunctiestoornis | Factor XI | ESRD (End-Stage Renal Disease)Verenigde Staten
-
Children's Oncology GroupNational Cancer Institute (NCI)VoltooidHeldercellig niercelcarcinoom | Stadium III niercelkanker | Stadium IV niercelkanker | Heldercellig sarcoom van de nier | Papillair niercelcarcinoom | Rhabdoïde tumor van de nier | Stadium I niercelkanker | Niercelcarcinoom bij kinderen | Stadium II niercelkanker | Stadium I Renal Wilms-tumor | Stadium II... en andere voorwaardenVerenigde Staten, Canada, Australië, Nieuw-Zeeland, Puerto Rico
Klinische onderzoeken op everolimus
-
Novartis PharmaceuticalsBeëindigdHepatocellulair carcinoomHongkong, Taiwan, Thailand
-
German Breast GroupNovartisBeëindigdUitgezaaide borstkankerDuitsland
-
The Netherlands Cancer InstituteActief, niet wervendNeuro-endocriene carcinomenNederland
-
Novartis PharmaceuticalsVoltooidLymfangioleiomyomatose (LAM) | Tubereuze Sclerose Complex (TSC)Verenigde Staten, Verenigd Koninkrijk, Duitsland, Italië, Russische Federatie, Nederland, Japan, Canada, Polen, Frankrijk, Spanje
-
University of LuebeckBeëindigdCoronaire hartziekteDuitsland
-
Novartis PharmaceuticalsVoltooidGastro-enteropancreatische neuro-endocriene tumor van het long- of gastro-enteropancreatische systeemDuitsland
-
Guangdong Provincial People's HospitalNovartisOnbekendNeuro-endocriene tumoren | Carcinoïde tumorChina
-
Asan Medical CenterVoltooidMaag NeoplasmaKorea, republiek van
-
Leiden University Medical CenterOnbekendHoofd-halskankerNederland
-
Novartis PharmaceuticalsBeëindigdCarcinoom, niercelAustralië, Korea, republiek van